Episode Summary
Executive Summary: Peter Attia interviews aging biologist Matt Kaeberlein about the Dog Aging Project, why companion dogs are a powerful model for human aging, and the promise and uncertainty of rapamycin as a healthy-aging intervention. They discuss dose, safety, immune effects, heart function, cancer, Alzheimer’s, microbiome changes, and the design of a large long-term dog trial.
Main Topics: Kaeberlein’s path into aging biology (Priority: 4/5): He moved from biochemistry/mathematics into aging research after hearing Lenny Guarente discuss yeast genetics of aging at MIT, then continued aging work in his postdoc and lab. Why dogs are a uniquely valuable aging model (Priority: 5/5): Dogs share human environments, have breed-based genetic diversity, and develop many of the same age-related diseases as people, making them a strong translational bridge beyond mice. Rapamycin as a candidate healthy-aging intervention (Priority: 5/5): The conversation centers on whether rapamycin can safely slow or reverse aspects of aging in healthy animals and eventually humans, with attention to dose, schedule, and side effects. Immune function, dosing, and the Novartis/MANIFEST-style data (Priority: 5/5): They examine why rapamycin can appear immunosuppressive in transplant settings yet improve vaccine responses in healthy older adults, and how trough levels may relate to side effects. Dog pilot study and cardiac outcomes (Priority: 5/5): Kaeberlein describes a small 10-week trial in healthy middle-aged dogs showing improved echocardiographic measures of heart function without major safety signals. Cancer, autophagy, and aging biology (Priority: 4/5): They debate whether rapamycin’s effects on autophagy and immune surveillance could help or hurt cancer risk, and how dose may shift outcomes differently in males and females. Future large-scale dog trial and translational implications (Priority: 5/5): The planned multi-site, five-year randomized trial would test lifespan and healthspan endpoints in dogs, potentially shaping public perception and future human trials.
Key Arguments: Aging can be studied mechanistically with genetics and biochemistry, not just described clinically; this is what first drew Kaeberlein to the field. Dogs are more translationally relevant than mice because they live in the same environment as humans and naturally develop many age-related diseases. Healthy-aging interventions require a different risk-benefit framework than disease treatment; some risk may be acceptable if it yields meaningful healthspan gains. Rapamycin’s effects appear dose-dependent, and side effects may be more related to trough exposure than peak exposure, though this is not fully proven. Rapamycin can improve immune responses in older adults despite its reputation as an immunosuppressant, likely because context, dose, and washout matter. Short-term rapamycin in old mice improves cardiac function, suggesting that some aging phenotypes may be partially reversible rather than merely slowed. The dog pilot study supports feasibility and suggests rapamycin may improve heart function in healthy middle-aged dogs without obvious short-term toxicity. Cancer biology is complicated: rapamycin may reduce cancer risk through improved immune surveillance at some doses, but very high doses may have adverse immune/cancer effects. Aging-related diseases like Alzheimer’s should be viewed as diseases of aging, not isolated disorders, which may explain why prior drug development has failed. A large, long-term dog trial could provide the strongest practical evidence for whether rapamycin meaningfully alters aging in a real-world mammalian environment.
Data Points: Years in aging research: Almost two decades - Kaeberlein says he has worked on aging biology for nearly 20 years. Dog pilot study duration: 10 weeks - Initial rapamycin trial in healthy companion dogs. Dog pilot study sample: 40 dogs screened; 24 completed - Dogs were enrolled at a private veterinary clinic; some were excluded for occult heart disease. Dog pilot study groups: 8 placebo, 11 high-dose, 5 low-dose - Final distribution of dogs completing the study. Rapamycin dog dose (high): 0.1 mg/kg three times weekly - Dose used in the highest-dose dog arm, Monday/Wednesday/Friday. Rapamycin dog dose (low): 0.05 mg/kg three times weekly - Lower-dose arm in the pilot dog study. Occult heart disease prevalence: About 20% - Dogs in the age/weight range had asymptomatic heart disease detectable by echocardiogram but not stethoscope. Mouse cardiac treatment window: 6 to 10 weeks - Rapamycin improved age-related cardiac function in old mice over this timeframe. Mouse high-dose aging study: 8 mg/kg daily injection - Described as the highest dose ever given in an aging study; called the 'party dose.' Mouse lifespan effect in males: 60% longer after treatment ended - In the high-dose, short-course mouse study, male mice lived substantially longer. Dog aging project interest: More than 6,000 sign-ups - Owners registered interest without advertising, indicating strong enthusiasm. Planned dog trial size: 450 dogs completed - Target for the proposed long-term randomized study. Planned dog trial screening: About 600 dogs screened - Estimated to yield 450 completers. Planned dog trial budget: About $5 million - Estimated cost for the five-year multi-site study. Rapamycin street value: About $7 per mg - Used to estimate drug cost in the proposed dog trial. Human immune trial doses: 20 mg weekly, 5 mg weekly, 1 mg daily - Dosing arms in the Novartis/everolimus study discussed as evidence for immune effects. Human immune trial washout: 2 weeks - Older adults stopped drug before vaccine-response testing in the study discussed. Dog age threshold: At least 6 years old - Eligibility criterion for the pilot dog study and proposed future trial. Dog weight threshold: At least 40 pounds - Eligibility criterion used because larger dogs age faster.
Pivotal Quotes: "“Could we do this safely?”" — Matt Kaeberlein: He describes the central concern before testing rapamycin in healthy dogs. "“Dogs really share our environment to a greater extent than any other animal.”" — Matt Kaeberlein: Explaining why companion dogs are a uniquely valuable translational model for aging research. "“A healthy 70-year-old is not the same as a healthy 30-year-old.”" — Matt Kaeberlein: Arguing for a different risk-benefit framework when intervening in aging rather than disease.
Implications: The episode argues that aging interventions may be testable in companion dogs before humans, with rapamycin as a leading candidate. If larger trials confirm benefit, it could reshape aging medicine, public perception, and future human prevention studies.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.